Unlike NF2-associated vestibular schwannomas, bevacizumab has been demonstrated to have limited benefit, with only a subset of patients demonstrating radiographic response which appears to be of limited duration [132,133]. The gene discussed is NF2; the disease is Vestibular schwannoma.